Physician profile
Christopher A Ney
NPI 1376822668
$39,506.07
in general payments reported to CMS, 2019-2025
32 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8,063 · 2022: $5,931 · 2023: $7,619 · 2024: $3,514 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $8,467 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,030 · Travel and Lodging: $2,692 · Education: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,553.76 |
| Consulting Fee | $8,467.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,030.00 |
| Travel and Lodging | $2,691.80 |
| Education | $768.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $9,915.29 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $9,499.00 | 2021-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $4,848.18 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $3,229.33 | 2021-2025 | |
| Janssen Biotech, INC. | $3,070.48 | 2021-2025 | Tremfya |
| Abbvie INC. | $2,218.73 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $790.37 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Genzyme Corporation | $738.24 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $663.48 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $640.66 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $597.13 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $507.20 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $505.40 | 2022-2025 | Sotyktu |
| Incyte Corporation | $454.87 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $380.73 | 2021-2025 | Nemluvio, Oracea, Aklief |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $337.04 | 2021-2025 | |
| Dermavant Sciences, INC. | $306.42 | 2023-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $95.45 | 2021-2025 | Cabtreo, Jublia, Arazlo |
| Vyne Pharmaceuticals INC. | $93.36 | 2021 | |
| Janssen Scientific Affairs, LLC | $90.14 | 2022 | |
| Biofrontera INC. | $75.82 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.48 | 2023-2024 | Spevigo |
| Botanix Sb INC | $66.19 | 2025 | Sofdra |
| Almirall LLC | $41.95 | 2023 | Klisyri, Seysara |
| Organon LLC | $33.86 | 2025 | |
| Dermira, INC. | $28.25 | 2021 | |
| Axonics, INC. | $26.73 | 2024 | Axonics |
| Iovance Biotherapeutics, INC. | $26.68 | 2025 | Amtagvi |
| Mayne Pharma Commercial LLC | $22.14 | 2022 | |
| Verrica Pharmaceuticals INC. | $18.29 | 2025 | Ycanth |
| Genentech USA, INC. | $13.19 | 2023 | Erivedge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.